Abstract
Overview
Introduction
This analysis examines the historical and forecast performance for J&J in the
ethical pharmaceutical sector. The profile encompasses global company
strategy, portfolio and pipeline analysis and assessment of financial
performance, with 1-6 year sales forecasts for key drugs. An interactive
forecasting and analysis tool provides continually updated quantitative and
qualitative information.
Reasons to Purchase
- Benchmark J&J' s performance against key rivals in the ethical
pharmaceutical sector
- See how the expiry of CNS blockbusters Risperdal and Topamax will result
in total sales decline despite the launch of an anticipated 16 new launches
View Cart
